Folliculin Controls Lung Alveolar Enlargement and Epithelial Cell Survival through E-Cadherin, LKB1, and AMPK

Elena A. Goncharova, Dmitry A. Goncharov, Melane L. James, Elena N. Atochina-Vasserman, Victoria Stepanova, Seung-Beom Hong, Hua Li, Linda Gonzalez, Masaya Baba, W. Marston Linehan, Andrew J. Gow, Susan Margulies, Susan Guttentag, Laura S. Schmidt, and Vera P. Krymskaya

INTRODUCTION

Birt-Hogg-Dubé (BHD) syndrome is a rare autosomal-dominant disorder that affects lung, skin, and kidney (Birt et al., 1977). In the lung, 80%–100% of patients with BHD develop multiple thin-wall cysts without evidence of neoplasia, inflammation, or fibrosis (Gupta et al., 2013). Cyst rupture and lung collapse cause spontaneous and recurrent pneumothoraces (Gupta et al., 2013). In contrast to lung, FLCN mutations in the kidney result in bilateral multifocal renal cell carcinomas (Schmidt, 2004), and in hair follicles result in hamartomas (fibrofolliculomas). The mechanism by which the loss of FLCN promotes the development of cysts but not neoplasia is unknown.

Genetic mapping in families with BHD identified the Folliculin (FLCN) gene locus (Nickerson et al., 2002; Schmidt et al., 2001). Loss of heterozygosity in BHD lesions supports a tumor suppressor function for FLCN (Vocke et al., 2005). Homozygous Flcn/C0 mice are embryonically lethal, and heterozygous Flcn+/− mice develop kidney tumors without lung pathology (Hasumi et al., 2008). In Drosophila and yeast, FLCN is involved in the mammalian target of rapamycin signaling pathway and in energy metabolism (Liu et al., 2013; van Slegtenhorst et al., 2007). Inactivation of FLCN induces mitochondrial gene expression (Hasumi et al., 2012). Studies also suggest crosstalk of FLCN with the master energy sensor AMP-activated protein kinase (AMPK) via FLCN-interacting proteins FNIP1 and FNIP2 (Baba et al., 2006; Hasumi et al., 2008; Takagi et al., 2008). How these signaling events relate to FLCN function in normal lung or in pulmonary cyst development in BHD is unknown.

The prevailing hypothesis used to explain the development of emphysematous alveolar enlargement and cyst formation in lung diseases involves an imbalance between matrix degrading matrix metalloproteinases (MMPs) and their endogenous inhibitors the tissue inhibitor of metalloproteinases (Shapiro and Ingenito, 2005; Suki et al., 2003). The notion, however, that alveolar epithelial cell (AEC) apoptosis is a primary event in the pathogenesis of alveolar enlargement related to lung injury has become an area of significant interest (Henson and Tuder, 2008; Mouded et al., 2009). The FLCN-dependent mechanism of cystic lung enlargement in BHD and the functional significance of FLCN inactivation in the lung remain uncharacterized.

Cell-cell and cell-matrix interactions are critical components of epithelial cell survival, and disruption of these interactions...
often leads to caspase-mediated apoptosis (Frisch and Screaton, 2001). AMPK is required for cell survival and for the maintenance of epithelial cell junctions (Hardie, 2011; Lee et al., 2008; Liu et al., 2010; Zheng and Cantley, 2007). AMPK activity is regulated through phosphorylation by LKB1 (Hardie, 2011), a tumor suppressor gene associated with 30% of lung cancers (Makowski and Hayes, 2008). LKB1 controls the maturation of apical junctions in human bronchial epithelial cells (Xu et al., 2013). E-cadherin regulates the localization of LKB1 to epithelial cell junctions, and loss of E-cadherin impairs LKB1-mediated AMPK activation (Sebbagh et al., 2009).

These observations raise the possibility that FLCN might be involved in the regulation of AMPK signaling in AECs and that inactivating mutation of FLCN might impair epithelial cell junctions and cell survival. In this study, we investigate this possibility with cell-type-specific inducible FlnC deletion in mouse lung epithelium and with FLNC-null human and mouse epithelial cell systems.

RESULTS

Loss of FlnC in Lung Epithelium Results in Increased Alveoli

Hematoxylin and eosin (H&E) staining of control human lung reveals typical lung structure (Figure 1A, left). In contrast, lungs from patients with BHD showed irregular and disrupted lung parenchyma (Figure 1A, right). Healthy alveoli are lined with type I and the surfactant protein C (SP-C)-expressing type II AECs (Figures S1A and S1B), a renewable population of progenitors in these distal airspaces. We used coimmunostaining to determine FLCN expression in human lung from healthy controls and subjects with BHD. In control lung, FLCN staining colocalizes with SP-C expression in AECs (Figure 1B, top). Coimmunostaining of lung tissue from patients with BHD detects very little FLCN in alveolar SP-C-positive cells (Figure 1B, bottom).
To evaluate the role of FLCN in lung, we selectively deleted \( \text{Fln} \) in SP-C-expressing alveolar epithelial type II cells (\( \text{Fln}^{f/f}; \text{SP-C-Cre} \)) by crossing \( \text{Fln}^{f/f} \) mice (Baba et al., 2009) with \( \text{SP-C-rtTA}\text{teto-Cre} \) (line 2) mice (Perl et al., 2000) (Figure S1C) to generate \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice with inducible \( \text{Fln} \) deletion in SP-C-expressing cells by a dietary supplementation with doxycycline (Dox) starting at 6 weeks of age. Under this SP-C promoter, Cre expression is targeted to the AECs in alveoli and peripheral bronchioles (Perl et al., 2009). \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice do not exhibit perinatal lethality or reduced survival, and weights were comparable across \( \text{Fln}^{f/f}; \text{SP-C-Cre}, \text{Fln}^{W/W}; \text{SP-C-Cre}, \) and \( \text{Fln}^{WT/W}; \text{SP-C-Cre} \) genotypes. The Dox diet did not affect mouse survival or weights and did not cause pulmonary distress. Genotyping, immunoblotting, and communostaining analyses of \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mouse lungs confirmed \( \text{Fln} \) deletion with the Dox diet (Figures 1C–1E, bottom). Immunoblotting (Figure 1D, Dox+ lanes) shows residual \( \text{Fln} \) expression in non-SP-C-expressing cells in whole-lung lysates. Importantly, inflation-fixed lungs from epithelial-specific \( \text{Fln} \)-deleted mice exhibited alveolar enlargement (Figure 2A).

Morphometric lung measurements of mean linear intercept (MLI) and mean alveolar airspace area (MAAA) are significantly larger in lungs of epithelial-specific \( \text{Fln} \)-deleted mice than in lungs of \( \text{Fln} \)-expressing \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice (Figures 2B, 2C, and S1D–S1F). However, the overall structure and organization of the lungs are nearly normal. The lung alveoli of \( \text{Fln}^{WT/W} \)-expressing \( \text{SP-C-Cre} \) or \( \text{Fln}^{WT/W} \)-deleted mice on a regular or Dox-supplemental diet appear unchanged and comparable with lung alveoli of \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice on a regular diet.

**FLCN Is Required for Postnatal Lung Alveolarization**

To determine the role of FLCN during lung development, female \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice were placed on a Dox-supplemented diet starting at embryonic day 0.5 (E0.5). Newborn pups were viable and appeared normal with no increased perinatal lethality. However, postnatal pups with lung epithelial-specific \( \text{Fln} \) deletion exhibited larger alveoli compared to pups with \( \text{Fln} \)-expressing lung epithelium (Figures 2D–2F). These data show developmental changes induced by \( \text{Fln} \) deletion in lung epithelium and suggest a role for FLCN in branching morphogenesis of the lung.

**FLCN Regulates Lung Function**

Morphological changes that resemble emphysema, such as alveolar enlargement, contribute to a decline in lung elastic recoil and pulmonary function. Lung function tests of adult \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice fed Dox for 6 weeks were markedly abnormal compared to age- and gender-matched littermates maintained on a regular diet. Decreased airway elastance and resistance and increased dynamic compliance were observed in \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice with \( \text{Fln} \) deletion in lung epithelium compared to \( \text{Fln} \)-expressing controls (Figure 2G).

To determine whether \( \text{Fln} \) loss in other lung epithelial cells might also impair lung function, we generated \( \text{Fln}^{f/f}; \text{CCSP-Cre} \) mice with targeted \( \text{Fln} \) deletion in lung epithelial cells expressing Clara cell secretory protein (CCSP) (Perl et al., 2009) (Figures S1G and S1H). CCSP-expressing lung epithelial cells localize in alveoli and bronchioles (Perl et al., 2009). \( \text{Fln} \) deletion in \( \text{Fln}^{f/f}; \text{CCSP-Cre} \) mice did not result in differences in the lung function (Figure S1I) compared to age- and gender-matched controls. These results demonstrate that lung parenchyma and function are affected by \( \text{Fln} \) deletion specifically in AECs expressing SP-C, and alveolar epithelium is vulnerable to loss of FLCN during early lung development as well as in the mature lung.

**FLCN Is Required for AEC Survival In Vivo**

To evaluate whether apoptosis plays a role in airspace enlargement in BHD, control and BHD human lung tissues were immunostained with cleaved caspase-3 antibody. As seen in Figure 2H, apoptotic SP-C-positive cells were detected in BHD lung, but not in control human lung. AECs positive for activated caspase-3 were identified in lungs of \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice maintained on a Dox diet compared to age- and gender-matched littermates maintained on a regular diet (Figure 2I). Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining to assess DNA fragmentation was also detected in human BHD lungs and mouse lungs with deleted FLCN (Figure S2). Importantly, TUNEL staining colocalizes with SP-C immunostaining (Figure S2C).

**FLCN Downregulates LKB1 and Controls AMPK Activity**

Because our results show that FLCN regulates AEC survival in vivo, we sought to identify the mechanism. AMPK activation is required to maintain epithelial cell-cell junctions, thus preserving epithelial barriers and promoting cell survival (Hardie, 2011). To determine whether FLCN deficiency affects AMPK activation, we used the FLCN-null human epithelial renal tumor cell line UOK257 derived from the kidney tumor of a patient with BHD, and UOK257 cells with stably re-expressed FLCN (UOK257-2) used as a control (Baba et al., 2006).

AMPK is phosphorylated on Thr172 by LKB1 under conditions of stress, such as nutrient deprivation. Serum depletion of FLCN-expressing UOK257-2 cells for 24 and 48 hr resulted in time-dependent AMPK phosphorylation at Thr172 (Figure 3A). Phosphorylation of acetyl-coenzyme A-carboxylase (ACC) by activated AMPK also increased in a time-dependent manner in FLCN-expressing UOK257-2 cells. In contrast, FLCN-null cells exhibited reduced AMPK activation and ACC phosphorylation compared to FLCN-expressing UOK257-2 cells (Figure 3A). Importantly, serum deprivation also increased cleaved caspase-3 in FLCN-null UOK257 cells, but not in FLCN-expressing UOK257-2 cells (Figure 3B).

To further examine the effect of FLCN loss on AMPK activation in lung epithelial cells, we isolated primary mouse AECs from lungs of \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice. Cells were treated with either an empty, replication-defective adenovirus or a replication-defective adenovirus expressing Cre-recombinase to delete \( \text{Fln} \) (Figure 4A). Immunostaining with antibody against T1α, an AEC marker (Ramirez et al., 2003), showed T1α expression in primary mouse AECs from \( \text{Fln}^{f/f}; \text{SP-C-Cre} \) mice (Figure S3). AMPK(Thr172) phosphorylation was significantly decreased in FLCN-null AECs in contrast to Fln-expressing AECs (Figure 4A). Small interfering RNA (siRNA)-induced \( \text{Fln} \) knockdown in mouse epithelial NMuMG cells also significantly decreased
Figure 2. Loss of FLCN Increases Pulmonary Alveoli, Impairs Lung Function, and Induces AEC Apoptosis

(A–C) Flcn loss results in alveolar enlargement in Flcn<sup>−/−</sup>:SP-C-Cre mice treated as in Figure 1D.

(D–F) Enlarged alveoli in pups with FLCN deletion in lung epithelium. In (B), (C), (E), and (F), the mean is shown; error bars represent SE (n > 3). Data for Dox−/C0 mice are taken as 1-fold.

(G) FLCN deletion in Flcn<sup>−/−</sup>:SP-C-Cre mice impairs lung function (n = 8 per group). BL, baseline; S, saline.

(H) Cleaved caspase-3-positive (red) cells in lung epithelium (SP-C, green) of BHD lung (n = 5), but not in control (n = 3) lung. Arrows indicate cleaved caspase-3 immunostaining of SP-C-positive cells in lungs from patients with BHD, but not in control lungs. Scale bars, 20 μM.

(I) Loss of Flcn in lung epithelium (SP-C, green) results in AEC apoptosis (red) in lung from Flcn<sup>−/−</sup>:SP-C-Cre mice treated as in Figure 1D (n = 3 per group). Arrows indicate cleaved caspase-3 immunostaining of SP-C-positive cells in Flcn<sup>−/−</sup>:SP-C-Cre mice on a Dox+, but not on a Dox−, diet. Scale bars, 20 μM.

See also Figure S2.
AMPK(Thr172) phosphorylation compared to cells transfected with control siRNA (Figure 4B).

We next examined LKB1 levels in cells deficient for FLCN because LKB1 activates AMPK via phosphorylation at Thr172-AMPK (Hardie, 2011). LKB1 levels were reduced in primary AECs after Flcn deletion (Figure 4A). LKB1 levels were also markedly decreased in NMuMG cells with Flcn knockdown induced by siRNA (Figure 4B). To further determine whether LKB1 expression is regulated by FLCN, FLCN-null UOK257 cells were transduced with replication-defective adenovirus expressing FLCN. FLCN re-expression in FLCN-null UOK257 cells significantly increased LKB1 levels (Figure 4C). Cellular fractionation showed significantly increased LKB1 levels induced by FLCN expression not only in cytosol but also in the membrane fraction (Figure 4C), confirming membrane localization of LKB1 (Sebbagh et al., 2009; Xu et al., 2013). These data suggest that FLCN regulates the cellular level and localization of LKB1.

**Regulation of E-Cadherin by FLCN**

Evidence demonstrates that E-cadherin regulates membrane localization of LKB1, which is critical for AMPK activation (Sebbagh et al., 2009). Therefore, we determined whether Flcn deletion in primary AECs would affect E-cadherin expression and/or localization. E-cadherin is significantly decreased in the absence of Flcn expression (Figures 5A–5C). Immunostaining also showed marked reduction of E-cadherin in the adherens junctions of cellular membranes (Figure 5D, top; Figures S4A and S4C). ZO-1 staining at tight junctions, however, appeared unchanged by Flcn deletion (Figure 5D, bottom; Figures S4B and S4C). Thus, FLCN has a specific effect on E-cadherin expression and localization to adherens junctions.

To further determine FLCN’s role in regulating E-cadherin, we used TSC2-null kidney epithelial cells, which have decreased membrane localization of E-cadherin (Figure 5E) (Barnes et al., 2010; Kleymenova et al., 2001). Transient transfection of TSC2-null cells with myc-tagged FLCN (Figure 5F) increased E-cadherin membrane localization, which was statistically significant (Figure 5G). These data further suggest that FLCN may play a role in regulation of E-cadherin.

**Increased FLCN-Null Epithelial Cell Permeability and Apoptosis**

Epithelial cell barriers and permeability depend on the preservation of adherens and tight junctions (Frisch and Screaton, 2001). Our data show reduced E-cadherin localization in the FLCN-null cellular membrane, which might affect adherens junctions. Hence, we examined whether FLCN is required for the maintenance of cell permeability. Primary AECs isolated from lungs of Flcn<sup>−/−</sup> mice were treated with empty adenovirus or Cre-recombinase-expressing adenovirus followed by a cell permeability assay using BODIPY-conjugated ouabain (DiPaolo and Margulies, 2012). Loss of Flcn resulted in increased permeability of primary AECs (Figure 5H) compared to cells expressing Flcn. In addition, loss of Flcn was associated with elevated cleaved caspase-3 levels and an increased number of cells with DNA fragmentation detected by TUNEL assay (Figures 5I–5K). These data demonstrate that FLCN is required for the maintenance of epithelial barrier integrity and AEC survival.

Similarly, mouse epithelial NMuMG cells transfected with siRNA Flcn exhibited decreased membrane localization of E-cadherin (Figures 6A and S5A), siFlcn also significantly decreased protein levels (Figure S5B) and cdh1 (E-cadherin)
and stk11 (LKB1) gene expression (Figures S5D and S5F). Furthermore, in cells transfected with siFlcn, E-cadherin does not maintain its multimeric structure as demonstrated by the presence of lower molecular weight staining under native conditions (Figure S5C), in contrast to no differences in LKB1 multimeric structure (Figure S5E) detected by native gel electrophoresis with equal loading of E-cadherin or LKB1 proteins.

Loss of Flcn in NMuMG cells also reduced transepithelial resistance (TER) (Figure 6B), another measure of increased cell permeability (Zheng and Cantley, 2007). We could not use TER to measure the permeability of primary AECs because they grow on the Matrigel-coated plates, which impede TER measurements. Finally, Flcn knockdown in NMuMG cells also increased cleaved caspase-3 levels (Figure 6C) and apoptosis (Figure 6D). Analysis of apoptotic gene expression using RT² Profiler PCR Arrays (SABiosciences; QIAGEN) revealed pro-apoptotic gene upregulation and decreased expression of prosurvival genes by Flcn knockdown (Figures S6A–S6C). Flcn-dependent downregulation of prosurvival Bcl-2 gene was further confirmed by decreased levels of Bcl-2 protein levels (Figure S6D). Collectively, our data show that FLCN regulates membrane localization of E-cadherin, protein, and gene expression, maintains epithelial barrier function, and preserves epithelial cell survival.

AICAR and Constitutively Active AMPK Rescue FLCN-Deficient Cell Survival

Flcn knockdown visibly changes epithelial cell morphology with disruption of the cell monolayer (Figure 6E). To evaluate the role of AMPK in FLCN-deficient cell survival, mouse epithelial NMuMG cells were transfected with siFlcn and then treated with 5-aminoimidazole-4-carboxamide riboside (AICAR), a cell-permeable precursor of AMP that activates AMPK (Figure 6G). Treatment with AICAR reversed Flcn-induced disruption of epithelial cell morphology (Figure 6E), AICAR treatment also significantly reduced Flcn-induced DNA fragmentation (Figure 6H) and epithelial cell death (Figure 6I). Similar results were seen upon transduction with adenovirus expressing the constitutively active AMPK (AdAMPK-CA) (Figure 6F) of NMuMG cells after Flcn knockdown. Expression of constitutively active AMPK markedly improved Flcn-deficient cell morphology (Figure 6E), reduced DNA fragmentation (Figure 6H), and rescued epithelial cell survival (Figure 6I). These results demonstrate that the kinase activity of AMPK is required for cell survival in the absence of FLCN.

**AICAR Improves Alveolar Surface Tension in Flcn<sup>f/f</sup>:SP-C-Cre Mice**

Our in vitro and in vivo data show that FLCN controls AEC survival. Alveolar type II cells are the only cells capable of manufacturing and secreting phospholipids into alveoli to reduce surface tension and support alveolar inflation at low lung volumes. We therefore measured surface tension and phospholipid composition obtained from bronchoalveolar lavage (BAL) of Flcn<sup>f/f</sup>:SP-C-Cre mice on a regular or Dox-supplemented diet. Total phospholipids measured in large aggregate (LA) fractions of BAL from mice with Flcn deletion in lung epithelium were reduced compared to control mice (Figure 7A). In addition, we measured surface tension of LA phospholipids from Dox-treated Flcn<sup>f/f</sup>:SP-C-Cre mice on a regular or Dox-supplemented diet. Total phospholipids measured in large aggregate (LA) fractions of BAL from mice with Flcn deletion in lung epithelium were reduced compared to control mice (Figure 7A). In addition, we measured surface tension of LA phospholipids from Dox-treated Flcn<sup>f/f</sup>:SP-C-Cre mice exhibited increased surface tension compared to untreated littermates, as evidenced by reduced capillary openness (Figure 7B). Importantly,
AICAR treatment improved phospholipid content and the surface tension of LA from Dox-treated Flcnf/f:SP-C-Cre mice (Figures 7A and 7B). There was a trend toward improved AEC survival, morphology, MLI, and MAAA in Dox-treated Flcnf/f:SP-C-Cre mice maintained on Dox and treated with AICAR compared to control mice also treated with AICAR (Figures 7C and 7E–7G, respectively). Thus, Flcn deletion in lung epithelium induces a physiologically significant aberration in surface tension of alveolar phospholipids that is stabilized by AICAR treatment.

Figure 5. Flcn Loss Reduces E-Cadherin Levels, Increases Cellular Permeability, and Promotes Apoptosis of Primary Mouse Lung AECs

(A–C) AdCre-induced Flcn deletion in AECs from Flcnf/f mice was detected by RT-PCR (A) and immunoblot (B) with statistical analysis (C). E-cadherin/tubulin ratio for control cells is taken as 1-fold.

(D) Loss of Flcn in AECs downregulates membrane localization of E-Cadherin (red, top), but not ZO1 (red, bottom) (as shown in arrowheads). DAPI (blue) stains nuclei.

See also Figure S4.

(F and G) FLNC expression (green) results in membrane localization of E-Cadherin (red) in TSC2-null cells (F). Data (G) represent percentage (% of cells) ≥60 cells/condition (F).

(H) Flcn deletion increases lung AEC permeability. Cell permeability in control is taken as 1-fold.

(I and J) Flcn deletion in lung AECs upregulates cleaved caspase-3.

(K) Flcn deletion in AECs results in DNA fragmentation. Number of TUNEL-positive cells to total number of cells is taken as 100%.

Data are mean ± SE (n > 3).

AICAR Suppresses Inflammation and MMP Levels

Increased inflammation and proteolytic degradation of extracellular matrix components such as basement membrane or interstitial stroma are pathological changes characteristic of emphysema. To test whether loss of Flcn was associated with increased inflammation, we examined the BAL fluid for inflammatory cell influx. After 2 weeks on a Dox diet, Flcnf/f:SP-C-Cre mice had increased numbers of total BAL cells compared with mice on a regular diet that was further increased by 6 weeks on Dox (Figures S6 and 7D). Importantly, Dox-treated Flcnf/f:SP-C-Cre mice treated with AICAR exhibited decreased inflammatory cell influx (Figure 7D).

We examined the proinflammatory cytokine profile of BAL from Dox-treated Flcnf/f:SP-C-Cre mice and untreated littermates to determine whether loss of FLCN alters cytokine expression. We found marked elevations in interleukin-6 (IL-6) and macrophage chemotactic protein-1 (MCP-1) in Flcnf/f:SP-C-Cre mice on Dox compared to untreated littermates (Figures 7H and 7I). There were no significant differences between control mice and mice with Flcn deletion in AECs in the levels of eotaxin, granulocyte-macrophage colony-stimulating factor, interferon γ, tumor necrosis factor α, IL-10, IL-13, IL-1β, keratinocyte chemoattractant, transforming growth factor β1, vascular endothelial growth factor, and macrophage inflammatory protein 1α (data not shown).

Moreover, AICAR treatment lowered levels of IL-6 and MCP-1 in BAL fluid of mice with Flcn knockout.

MMPs represent a family of structurally and functionally related enzymes responsible for the proteolytic degradation of extracellular matrix and have been mechanistically linked with progressive pulmonary emphysema and chronic inflammation. BAL from Dox-treated Flcnf/f:SP-C-Cre mice demonstrated significant elevations of MMP-3 and MMP-9 compared to untreated mice (Figures 7J and 7K). Furthermore, treatment with AICAR lowered MMP-3 and MMP-9 levels to levels comparable to control mice (Figures 7J and 7K). Collectively, in vivo experiments demonstrate that Flcn inactivation in lung AECs of Flcnf/f:SP-C-Cre mice evokes inflammatory response and upregulation of MMP-3 and MMP-9 in a manner that is reversible with exogenous AMPK activation by AICAR.
DISCUSSION

The present study identifies FLCN as a regulator of lung homeostasis and advances our understanding of the pathophysiology of emphysema. This study details the cellular and molecular mechanisms by which FLCN contributes to lung epithelial cell survival, thereby maintaining alveolar surface tension through maintenance of phospholipid production. As such, loss of FLCN leads to loss of epithelial cells with resultant reduction in phospholipid production that contributes to the lung changes associated with BHD (Figure 7L). Furthermore, we show that FLCN maintains epithelial cell junctions and survival in an AMPK-dependent fashion by regulating membrane localization of E-cadherin and LKB1 (Figure 7L).

The abnormal enlargement of airspaces is a major pathological manifestation of many common and rare lung diseases, including emphysema, cystic fibrosis, chronic obstructive pulmonary disease (COPD), pulmonary lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocytosis (PLCH), lymphocytic interstitial pneumonia (LIP), follicular bronchiolitis, light-chain deposition disease, Sjögren’s syndrome, and amyloidosis (Gupta et al., 2013). It is becoming increasingly clear that the mechanisms underlying the development of emphysematous changes in the lung are more complex than simply an imbalance of proteolysis and antiproteolysis. Together, our data provide additional supportive evidence for the complex pathophysiology of emphysematous alveolar enlargement by showing that FLCN supports cell survival and influences the cytokine and MMP milieu in ways that might contribute to lung cyst formation with loss of FLCN in BHD. These insights into the role of FLCN may serve as a foundation for novel therapeutic approaches for BHD and other emphysematous lung diseases.

This study establishes that FLCN plays an important physiological role in regulating AEC survival and alveolar integrity. We demonstrate the importance of FLCN for AEC apoptosis in vivo and in vitro using Flcnfl/fl:SP-C-Cre mice, by examining both lung tissue and isolated AECs. It is intriguing that Flcn loss in an immortalized mouse embryonic stem cell line resulted in transcriptional downregulation of proapoptotic protein Bim (Cash et al., 2011). Elucidating a more direct role for Flcn intersecting with apoptotic pathways will be possible in the future with our cell and mouse models.
Our studies clearly demonstrate that the prosurvival role is mediated through AMPK (Figure 7L). The prosurvival role of AMPK in epithelial cells is well established, especially as related to the maintenance of epithelial contacts and polarity (Zhang et al., 2006; Zheng and Cantley, 2007). Phosphorylation of AMPK by tumor suppressor LKB1 increases AMPK activity (Jansen et al., 2009). This requires the localization of LKB1 to E-cadherin at adherens junctions (Sebbagh et al., 2009). Evidence suggesting a role for AMPK in microtubule formation via CLIP-170 (Nakano et al., 2010), which also has a role in E-cadherin localization (Barnes, 2010), provides a reinforcing loop of E-cadherin/LKB1/AMPK regulation of apical polarity.

Figure 7. AICAR Improves Lung Homeostasis of Flcn<sup>−/−</sup>:SP-C-Cre Mice with Flcn Deletion in Lung Epithelium

(A) Abnormalities in pulmonary phospholipids in BAL resulting from Flcn deficiency are restored by AICAR. Flcn<sup>−/−</sup>:SP-C-Cre mice on Dox<sup>−</sup> or Dox+ were treated with AICAR or diluent for 6 weeks. (B) Flcn-induced impairment of surfactant surface tension is rescued by AICAR. (C) Flcn loss induces DNA fragmentation of AECs. Number of TUNEL-positive cells to total number of cells was taken as 100%. (D) AICAR normalizes increased inflammatory cell influx. (E) H&E staining of Flcn<sup>−/−</sup>:SP-C-Cre mouse lungs on Dox<sup>−</sup> or Dox+ treated with AICAR as in (A). The mean is shown; error bars represent SE (n > 3). Data for Dox<sup>−</sup> mice are taken as 1-fold. (F and G) Morphometric analyses of Flcn<sup>−/−</sup>:SP-C-Cre mouse lungs treated as in (A). (J and K) Upregulation of MMP-3 and MMP-9 induced by Flcn loss in lung epithelium treated as in (A) is abrogated by AICAR. (L) A proposed model for the role of FLCN in lung alveolar homeostasis. FLCN mutations in lung epithelium downregulate membrane localization of E-cadherin and LKB1, which impairs AMPK activation. This model proposes that FLCN plays an important physiological function to control AEC survival and maintains alveolar surface tension. Loss of FLCN results in alveolar collapse and impairment of lung function. See also Figure S7. Data in (A)–(K) are represented as mean ± SEM from two independent experiments (n = 5–7).

Our data suggest that FLCN promotes survival of AECs through this E-cadherin/LKB1/AMPK axis. Our data also suggest that FLCN functions upstream of AMPK. Loss of FLCN affects assembly of adherens junctions via downregulation of E-cadherin levels while having little effect on ZO1 levels in tight junctions. Importantly, disruption of the epithelial monolayer and apoptosis caused by FLCN loss were prevented by either molecular or pharmacological AMPK activation. Together with published studies, our data suggest that FLCN is required for E-cadherin-dependent epithelial cell-cell junctions, impairment of LKB1-AMPK signaling, and caspase-dependent apoptosis of lung AECs, the initial component of alveolar airspace enlargement. Further studies will provide detailed mechanisms of how FLCN regulates E-cadherin and LKB1 expressions.

One consequence of altered AEC survival is the loss of an important source of pulmonary phospholipids. Phospholipids play an important role in the maintenance of alveolar stability through the respiratory cycle, so it is perhaps not surprising that apoptosis-induced airspace enlargement is associated
with increased alveolar surface tension, and alveolar instability and collapse (Mouded et al., 2009). However, this raises an important therapeutic possibility, specifically the potential for exogenous phospholipid therapy to mitigate the effects of AEC loss. Although exogenous phospholipid therapy for unintubated patients is currently unfeasible due to issues of delivery, novel delivery modalities or therapies targeting increased production of phospholipid by the remaining epithelial cell population are attractive options for the future.

The loss of FLCN also evokes an inflammatory response associated with local production of inflammatory cytokines and MMPs. Further studies will determine whether this is due to an epithelial injury response, or whether FLCN itself signals an anti-inflammatory pathway.

FLCN acts through an AMPK-mediated pathway that can be resurrected by exogenous activation of AMPK. AICAR, an AMPK activator, reverses many of the pathologic changes in the Flcn−/−:SP-C-Cre mice with Flcn deletion limited to lung AECs. Importantly, AICAR rescues those features of Flcn loss that are critical to the pathophysiology of lung cysts, specifically mitigating inflammation and MMP expression that propagate local alveolar damage and enhancing phospholipid production to stabilize airspace inflation. Although AMPK-dependent suppression of MMP-9 has been previously reported by Hwang and Jeong (2010) and Morizane et al. (2011), our data provide an attractive mechanism for a feedforward cycle of epithelial cell destabilization with loss of FLCN followed by further local destruction by enhanced MMP production. Further studies are needed to establish the mechanism(s) whereby impaired AMPK signaling increases MMP expression.

Rescue by AICAR does not reverse the structural changes due to Flcn loss. It does not rule out the possibility that AMPK agonists may have a role in prevention or that they may be useful to stop or slow the progression of existing emphysema.

There are several limitations of our studies. First, Flcn deletion in Flcn−/−:SP-C-Cre mice does not precisely phenocopy lung changes in patients with BHD. Patients with BHD exhibit loss of alveoli and lung cyst development predominantly localized to the lower regions of the lung (Gupta et al., 2013). The differences between our mouse model and human patients may be due to either the restricted knockout of Flcn in epithelial cells only or the expression of nonnull mutations of FLCN in patients with BHD. Despite these limitations, our data demonstrate the key role of FLCN in the maintenance of normal lung parenchyma architecture and physiology, and a well-defined mechanism whereby FLCN, acting through E-cadherin, LKB1, and AMPK, has a critical role in regulating the assembly of epithelial cell junctions.

EXPERIMENTAL PROCEDURES

The Human Lung Tissue
Control human lung tissues from three subjects were obtained from the National Disease Research Interchange, and the human BHD tissue samples from four patients with BHD were obtained from the NIH under approved protocols.

Animals
Flcn−/−:SP-C-Cre mice were generated by crossing Flcn−/− mice (Baba et al., 2008) with SP-C-rtTA/tetO-Cre (line 2) mice (Peri et al., 2009). Flcn−/−:CCSP-Cre mice were generated by crossing Flcn−/− mice with CCSP-rtTA/tetO-Cre mice (line 2) (Peri et al., 2009). Genotyping was performed as described (Baba et al., 2008). Six-week-old male Flcn−/−:SP-C-Cre or Flcn−/−:CCSP-C-Cre mice were transferred on chow supplemented with 2.5% Dox (Dox−) or maintained on a regular chow (Dox+) for 3 or 6 weeks. Treatment with 500 mg/kg AICAR was performed daily by intraperitoneal injections for 6 weeks in mice on Dox− or Dox+ diet.

Ballooning function was measured on a computerized FlexiVent System (SCIREQ, Haczu et al., 2002). For morphological analyses, lungs were inflated at constant 25 cm H2O pressure with 1:1 optimal cutting temperature/PBS or low-melting agarose in PBS for approximately 8 min (Goncharova et al., 2012). Each experimental group included a minimum of five animals per condition. Experiments to determine the effects of Flcn loss on alveoli space enlargement were performed three times, and experiments with treatment by AICAR were performed twice. All animal procedures were performed according to a protocol approved by the University of Pennsylvania IACUC.

BAL Analyses
BAL fluid was collected by lavaging the lung with 1 ml of sterile saline to a total of 5 ml. Recovered BAL was centrifuged 400 g for 10 min at 4°C; then cell pellet was resuspended in 1 ml PBS for total cell count. Cell-free BAL supernatants were separated by centrifugation at 20,000 g for 60 min at 4°C into LA and small-aggregate (SA) phospholipid fractions. Surface tension was determined by measuring capillary openness with a capillary surfactometer (Calma Medical) (Guttentag et al., 2005). Briefly, 0.5 µl of 1 mg/ml LA was deposited into the glass capillary and compressed for 120 s, resulting in a cyclic extrusion from the narrow end of the capillary permitting airflow and capillary patency. Dysfunctional phospholipids exhibit decreased capillary patency that is inversely correlated with the surface tension. A microprocessor calculates the percentage of the 120 s period that the capillary is open to free airflow. Each sample was analyzed in triplicate. Cytokine and MMPs were determined in the cell-free BAL by SearchLight Multiplex ELISA at Aushon Biosystems.

Morphometry
Images of lung tissue sections stained with H&E were acquired with a Nikon Eclipse 80i microscope under 100x magnification. Ten randomly selected fields per slide from three nonserial sections were analyzed. Image-Pro Plus 6.2 software (Media Cybernetics) was used to measure the MAAA and MLI. Airway, vascular structures, and histological mechanical artifacts were eliminated from the analysis.

Immunohistochemical, immunocytochemical, and immunoblot analyses were performed as described (Goncharova et al., 2011). Immunostaining was visualized with a Leica SP5 X or Zeiss LSM 700 confocal microscope or a Nikon Eclipse TE2000-E microscope equipped with an Emission QEI digital video camera under appropriate filters. Protein levels were analyzed by optical density with Gel-Pro Analyzer software.

Cell Culture
AECs were isolated from 2-week-old Flcn−/− mice as described (Atochina-Vasserman et al., 2011). Mouse lungs were inflated in situ via tracheal cannulation with dispase. Dissected lobes were digested in modified Eagle’s medium plus DNase I. The mixed cells were filtered, and fibroblasts were removed from the suspension by three successive adherence steps on plastic. Negative selection was used to purify epithelial cells from macrophages and other blood cells using magnetic beads (Dynal Mouse T Cell Negative Isolation Kit #114.13D). Cells were plated in HITES medium (prepared in Ham’s F12 plus 15 mM HEPES, 0.8 mM CaCl2, hydrocortisone, and [β-estradiol] plus 10% fetal calf serum (FCS) on coverslips coated with 10% Matrigel (BD Biosciences) for immunofluorescence staining. Serum was added for 48 hr to facilitate adherence and was then removed to minimize overgrowth of any remaining fibroblasts. Human UOK-257 and UOK257-2 cell lines (Hong et al., 2010) and TSC2-null kidney epithelial cells from an Eker rat were prepared as described.
bodies (Kleymenova et al., 2001); mouse epithelial NMuMG cells were purchased from the American Type Culture Collection.

Finc siRNA was from Dharmacon, and scrambled siRNA was from Santa Cruz Biotechnology. Transfection was performed using Effectene or RNAiFect reagents (QIAGEN). Infection with AdCre or AdFLCN adenovirus was described (Goncharova et al., 2004).

BODIPY Permeability Assay

The assay was performed as described (DiPaolo and Margulies, 2012). Briefly, 2 μM BODIPY-ouabain (Invitrogen) was added to AECs for 1 hr. Then BODIPY-ouabain fluorescence was visualized using a green emission filter. Fluorescence was measured on four separate fields per well, and three wells were measured per condition. All measurements were normalized to values from cells infected with control adenovirus.

TER Measurements

TER was measured in confluent NMuMG cells, grown on electric cell substrate impedance-sensing (ECIS) 8W1E plates, then subjected to an elevated voltage pulse of 40 kHz frequency, 3.5 V amplitude for 30 s (Taliaferro-Smith et al., 2009).

Data Analysis

Data points from individual assays represent mean ± SE. Statistically significant differences among groups were assessed with ANOVA (with the Fisher post hoc test) least significant different test), with values of p < 0.05 to sufficiently reject the null hypothesis for all analyses. In Figures 7 and S7, statistically significant differences among groups were assessed with t test (n = 5–7 animals per group). All experiments were designed with matched control conditions within each experiment (minimum of five animals) to enable statistical comparison as paired samples and to obtain statistically significant data.

SUPPLEMENTAL INFORMATION

Supplemental Information includes several figures and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2014.03.025.

ACKNOWLEDGMENTS

We thank Dr. Jeffrey A. Whitsett (Cincinnati Children’s Hospital Medical Center) for generously providing SP-C-rtTA/tetO-Cre (line 2) mice and C57SP-rtTA/tetO-Cre (line 2) mice; Dr. Cheryl Walker (Texas A&M Health Science Center) for the generous gift of rat TSC2-null cells; Dr. Leslie A. Litzkry (University of Pennsylvania) for help with tissue specimens from patients with BHD; Dr. Chang-Jiang Guo and Helen Abramova (Rutgers University) for excellent technical support; Ms. Sharmin Islam for preparing Figure S1 A; BHD; Dr. Chang-Jiang Guo and Helen Abramova (Rutgers University) for help with tissue specimens from patients with BHD; Dr. Chang-Jiang Guo and Helen Abramova (Rutgers University) for excellent technical support; Ms. Sharmin Islam for preparing Figure S1 A; and Mr. Nathan Tessema Ersumo for exceptional help with Figures 1 and 2, the graphical abstract, slider image, and technical assistance with the manuscript. This research was supported by the Intramural Research Program of the National Institutes of Health, Frederick National Laboratory for Cancer Research, and the Center for Cancer Research. This project has been funded in whole or in part with federal funds from the National Institutes of Health, National Cancer Institute, and the National Heart, Lung, and Blood Institute. The content of this publication does not necessarily reflect the views or policies of the DHHS, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This work was supported by NIH/NHLBI R01 HL110551 (to V.P.K.) and the Myovrylon Trust (to S.-B.H. and V.P.K.).

Received: September 13, 2013
Revised: January 30, 2014
Accepted: March 10, 2014
Published: April 10, 2014

REFERENCES


